Table 1.
Baseline patient characteristics after propensity score matching
| No. (%) or Median (range) | P | ||
|---|---|---|---|
| HCVAD + ponatinib [n=41] | HCVAD + dasatinib [n=41] | ||
| Age, (y) | 57 (27-80) | 55 (22-75) | 0.68 |
| White blood cell count (×109/L) | 8.5 (0.9-629.4) | 12.2 (0.4-658.1) | 0.87 |
| Performance status | |||
| 0-1 | 35 (85) | 37 (90) | 0.74 |
| ≥2 | 6 (15) | 4 (10) | |
| Cytogenetic abnormalities | |||
| Isolated Ph+ | 6 (15) | 6 (15) | 0.98 |
| Ph+ and other | 29 (71) | 28 (68) | |
| Diploid, (Ph+ by FISH/PCR) | 3 (7) | 3 (7) | |
| Unknown, (Ph+ by FISH/PCR) | 3 (7) | 4 (10) | |
| Transcript subtype | |||
| B2A2 | 4 (10) | 5 (12) | 0.39 |
| B3A2 | 4 (10) | 1 (2) | |
| B2A2 + B3A2 | 1 (2) | 1 (2) | |
| E1A2 | 30 (73) | 34 (83) | |
| E1A3 | 2 (5) | 0 | |
| CD20 positivity, (%) | 8.9 (0-100) | 15.2 (0-98) | 0.61 |
| Rituximab therapy | 14 (34) | 12 (29) | 0.64 |
| CNS disease | 3 (7) | 3 (7) | 1.00 |
Abbreviations: HCVAD, hyper-CVAD; Ph+, Philadelphia chromosome-positive; FISH, fluorescence in situ hybridization; PCR, polymerase chain reaction; CNS, central nervous system